Company / Operating Cash Flow
Arbutus Biopharma Corp Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$39.6M
FY2025
5-year range
-$85.9M / -$35.4M
FY2021-FY2025
Trend
+38.9%
vs FY2024
Sector context
#91 of 216
Health Care
What the data says
At -$40M, Arbutus Biopharma Corp's operating cash flow ranks #91 of 216 in the Health Care sector. Operating Cash Flow has fluctuated over the past 10 years, ranging from -$86M in FY2023 to -$35M in FY2022.
Based on SEC 10-K filings.
-$40M in FY2025.
Improved from -$86M to -$40M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#91 of 216 in Health CareTop 42% of 216This company -$39.6M Sector average $658.7M
▼
-106.0% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow increased 38.9% year-over-year.
- Ranks #91 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2022.
- Lowest operating cash flow in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -11.01 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$39.6M | +38.9% |
| FY2024 | -$64.8M | +24.5% |
| FY2023 | -$85.9M | -143.1% |
| FY2022 | -$35.4M | +47.6% |
| FY2021 | -$67.5M | +4.9% |
| FY2020 | -$71.0M | -4.6% |
| FY2019 | -$67.9M | -39.5% |
| FY2018 | -$48.6M | +0.0% |
| FY2017 | -$48.6M | +16.0% |
| FY2016 | -$57.9M | -2.7% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026